It was shown that reducing the levels of APOJ in the bloodstream resulted in reducing resistance to treatments such as sorafenib/doxorubicin, while increasing the levels of APOJ leads to increasing metastasis and tumor growth [152]. The gene discussed is CLU; the disease is neoplasm.